SCHEMBL1651850

SCHEMBL1651850

O=C(CCC(=O)c1ccco1)c1ccco1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.70
CES1 P23141 1/20 0.70
ALDH1A1 P00352 6/20 0.62
POLB P06746 5/20 0.62
HPGD P15428 5/20 0.62
HSD17B10 Q99714 4/20 0.62
RECQL P46063 3/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
ALOX15 P16050 3/20 0.62
TDP1 Q9NUW8 2/20 0.62
ERCC5 P28715 1/20 0.62
FEN1 P39748 1/20 0.62
MAPT P10636 1/20 0.62
PTPN1 P18031 1/20 0.61
CTNNB1 P35222 7/20 0.60
WNT3A P56704 7/20 0.60
CYP2D6 P10635 1/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
THRB P10828 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28064749 0.94 CES2 (0.61) CES2CES1ALDH1A1POLBHPGD
SCHEMBL7718179 0.92 ERCC5 (0.59) CES2CES1ALDH1A1POLBHPGD
SCHEMBL8544013 0.91 CES2 (0.64) CES2CES1ALDH1A1POLBHPGD
SCHEMBL8962313 0.90 CES2 (0.57) CES2CES1ALDH1A1POLBHPGD
SCHEMBL5527395 0.90 CES2 (0.57) CES2CES1ALDH1A1POLBHPGD
SCHEMBL2526232 0.89 CES2 (0.61) CES2CES1ALDH1A1POLBHPGD
SCHEMBL15979683 0.88 CTNNB1 (0.59) CES2CES1ALDH1A1POLBHPGD
SCHEMBL27398867 0.87 CES2 (0.59) CES2CES1ALDH1A1POLBHPGD
SCHEMBL3506264 0.87 CES2 (0.59) CES2CES1ALDH1A1POLBHPGD
SCHEMBL1933054 0.87 CES2 (0.59) CES2CES1ALDH1A1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-12 US disclosed
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-12 US disclosed
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2023-02-23 US disclosed
US-20220087917-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES VICKERS VENTURE FUND VI PTE. LTD. (SG) 2022-03-24 US disclosed
US-11077046-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles BIOSPLICE THERAPEUTICS, INC. (US) 2021-08-03 US disclosed
US-11034682-B2 Gamma-diketones as wnt/β-catenin signaling pathway activators SAMUMED, LLC (US) 2021-06-15 US disclosed
EP-3283550-B1 CATALYST CONTAINING AMIDINE GROUPS SIKA TECH AG (CH) 2020-12-16 EP disclosed
EP-3294803-B1 GUANIDINE GROUP CONTAINING CATALYST SIKA TECH AG (CH) 2020-12-09 EP disclosed
US-20110082248-A1 POLYAMINE HAVING A REDUCED BLUSHING EFFECT, AND USE THEREOF AS A CURING AGENT FOR EPOXY RESINS SIKA TECHNOLOGY AG (CH) 2011-04-07 US disclosed
EP-2133378-A1 Polyamine with reduced blushing and its application as hardener for epoxy resin Sika Technology AG (CH) 2009-12-16 EP disclosed
EP-2133381-A1 Water soluble amine and its application Sika Technology AG (CH) 2009-12-16 EP disclosed
EP-0500005-B1 Process for the preparation of substituted indenes HOECHST AG (DE) 1996-02-07 EP disclosed
US-5194619-A PROCESS FOR THE PREPARATION OF SUBSTITUTED INDENES HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-16 US disclosed
EP-0500005-A1 Process for the preparation of substituted indenes HOECHST AKTIENGESELLSCHAFT (DE) 1992-08-26 EP disclosed
EP-0199324-B1 NEW 2,5-DIARYL TETRYHYDROFURANS AND ANALOGS THEREOF AS PAF ANTAGONISTS MERCK & CO. INC. (US) 1991-10-02 EP disclosed
EP-0322033-A2 New 2,5-diaryl tetrahydrofurans and analogs thereof as paf antagonists MERCK & CO. INC. (US) 1989-06-28 EP disclosed
EP-0199324-A2 New 2,5-diaryl tetryhydrofurans and analogs thereof as paf antagonists MERCK & CO. INC. (US) 1986-10-29 EP disclosed
US-4035395-A Process for the preparation of ketones BAYER AKTIENGESELLSCHAFT (DT) 1977-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11077046-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles GLA, DGKG, DGKA CES2 4435/4885CES1 2510/4885ALDH1A1 985/4885
US-20220087917-A1 GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES GLA, DGKG, DGKA CES2 4435/4885CES1 2510/4885ALDH1A1 985/4885
US-20110082248-A1 POLYAMINE HAVING A REDUCED BLUSHING EFFECT, AND USE THEREOF AS A CURING AGENT FOR EPOXY RESINS SRM, PRMT1, PBRM1 CES2 1022/4885CES1 1777/4885ALDH1A1 287/4885
US-11839679-B2 Gamma-diketones for treatment and prevention of aging skin and wrinkles DGKG, DGKA, DNER CES2 3982/4885CES1 2355/4885ALDH1A1 1485/4885
US-20230053726-A1 GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS GSK3A, GSK3B, WNT1 CES2 4753/4885CES1 3944/4885ALDH1A1 1019/4885
US-11034682-B2 Gamma-diketones as wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 CES2 4768/4885CES1 4001/4885ALDH1A1 1024/4885
US-11673885-B2 γ-diketones as Wnt/β-catenin signaling pathway activators GSK3A, GSK3B, WNT1 CES2 4749/4885CES1 3997/4885ALDH1A1 1093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.